Fig 1.
Participant enrollment flow diagram.
MR; magnetic resonance.
Table 1.
Adoptive immune-cell therapy-related adverse events.
Fig 2.
(A) overall survival (OS) and (B) progression free survival (PFS) of 14 patients with recurrent GBM who received the adoptive immune-cell therapy. (C) OS and PFS of good (n = 5) and poor responders (n = 9). (D) Therapeutic response assessment of one patient with recurrent GBM multiforme (A7) who received the adoptive immune-cell therapy with two different tumor lesions (frontal and temporal lobes) and showed good prognosis (overall survival: 46 months). Results of magnetic resonance imaging for evaluating the response to adoptive immune-cell therapy in the frontal and temporal lobes during injection of adoptive immune-cell and follow-up after completion. IDH1; isocitrate dehydrogenase, GTR; gross total resection, NTR; near-total resection, ChemoTx; chemotherapy, BCNU; carmustine, ACNU; nimustine, Re-RTx; re-irradiation therapy.
Table 2.
Clinical information of good responders and poor responders.
Fig 3.
Cluster maps of four annotation terms (A-D) that fully discriminated between good (A1, A6, A7, A11, and A14) and poor responders. The expression levels of the genes were transformed into a 0–1 standard scale. (A) Immune cell localization to tumors, (B) recognition of cancer cells by T-cells, (C) common signaling pathways, (D) myeloid cell activity.